JPWO2024204685A1 - - Google Patents
Info
- Publication number
- JPWO2024204685A1 JPWO2024204685A1 JP2024521768A JP2024521768A JPWO2024204685A1 JP WO2024204685 A1 JPWO2024204685 A1 JP WO2024204685A1 JP 2024521768 A JP2024521768 A JP 2024521768A JP 2024521768 A JP2024521768 A JP 2024521768A JP WO2024204685 A1 JPWO2024204685 A1 JP WO2024204685A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21001—Chymotrypsin (3.4.21.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21004—Trypsin (3.4.21.4)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023056981 | 2023-03-31 | ||
| PCT/JP2024/012990 WO2024204685A1 (ja) | 2023-03-31 | 2024-03-29 | 癌の治療および／または予防のための医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2024204685A1 true JPWO2024204685A1 (enExample) | 2024-10-03 |
Family
ID=92905821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024521768A Pending JPWO2024204685A1 (enExample) | 2023-03-31 | 2024-03-29 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4691490A1 (enExample) |
| JP (1) | JPWO2024204685A1 (enExample) |
| KR (1) | KR20250163299A (enExample) |
| CN (1) | CN120957748A (enExample) |
| AU (1) | AU2024246833A1 (enExample) |
| MX (1) | MX2025010488A (enExample) |
| WO (1) | WO2024204685A1 (enExample) |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| KR100261941B1 (ko) | 1994-07-13 | 2000-07-15 | 나가야마 오사무 | 사람의 인터루킨-8에 대한 재구성 사람항체 |
| AU752730B2 (en) | 1998-04-03 | 2002-09-26 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| ATE499948T1 (de) | 2001-01-12 | 2011-03-15 | Novartis Vaccines & Diagnostic | Nukleinsäure mukosale immunisierung |
| EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| DE10359795A1 (de) | 2003-12-19 | 2005-07-21 | Bayer Technology Services Gmbh | Strangverdampfervorrichtung |
| WO2006107903A2 (en) | 2005-04-01 | 2006-10-12 | Intezyne Technologies, Incorporated | Polymeric micelles for drug delivery |
| AU2006311912A1 (en) | 2005-11-04 | 2007-05-18 | Mdrna, Inc. | Peptide-dicer substrate RNA conjugates as delivery vehicles for siRNA |
| PL2285350T3 (pl) | 2008-06-16 | 2018-03-30 | Pfizer Inc. | Sposoby otrzymywania funkcjonalizowanych kopolimerów dwublokowych stanowiących środki kierujące do stosowania przy wytwarzaniu nanocząstek terapeutycznych |
| ES2765240T3 (es) | 2008-06-16 | 2020-06-08 | Pfizer | Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas |
| PT2322221E (pt) | 2008-08-05 | 2014-09-19 | Toray Industries | Composição farmacêutica para tratamento e prevenção de cancro |
| BRPI0911925B8 (pt) | 2008-08-05 | 2024-02-06 | Toray Industries | Método para detectar um câncer |
| WO2011005481A1 (en) | 2009-06-22 | 2011-01-13 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
| US8642292B2 (en) | 2009-09-22 | 2014-02-04 | Probiogen Ag | Process for producing molecules containing specialized glycan structures |
| KR101805520B1 (ko) | 2010-02-04 | 2017-12-07 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| US8709418B2 (en) | 2010-02-04 | 2014-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treating CAPRIN-1 expressing cancer |
| CA2788716C (en) | 2010-02-04 | 2019-06-18 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| BR112012018943A8 (pt) | 2010-02-04 | 2017-12-19 | Toray Industries | medicamento e método para o tratamento e/ou prevenção de um câncer |
| ES2583627T3 (es) | 2010-02-04 | 2016-09-21 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la prevención del cáncer |
| PL2532364T3 (pl) | 2010-02-04 | 2016-11-30 | Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi | |
| MX341925B (es) | 2010-03-29 | 2016-09-07 | Zymeworks Inc | Anticuerpos con funcion efectora suprimida o mejorada. |
| WO2013018886A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 膵臓癌の治療及び／又は予防用医薬組成物 |
| RU2624049C2 (ru) | 2011-08-04 | 2017-06-30 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественной опухоли |
| RU2595400C2 (ru) | 2011-08-04 | 2016-08-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
| HUE030137T2 (en) | 2011-08-04 | 2017-04-28 | Toray Industries | Pharmaceutical preparation for the treatment and / or prevention of cancer |
| MX348578B (es) | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |
| ES2634249T3 (es) | 2011-08-04 | 2017-09-27 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer |
| CA2864999C (en) | 2012-02-21 | 2020-06-30 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| EP2818483B1 (en) | 2012-02-21 | 2017-08-02 | Toray Industries, Inc. | Medicinal composition for treating and/or preventing cancer |
| US9273130B2 (en) | 2012-02-21 | 2016-03-01 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| MX360211B (es) | 2012-02-21 | 2018-10-24 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| CN104220095B (zh) | 2012-03-30 | 2016-09-07 | 东丽株式会社 | 肝癌的治疗和/或预防用药物组合物 |
| CA2869123C (en) | 2012-03-30 | 2021-03-16 | Toray Industries, Inc. | Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| EP3031826B1 (en) | 2013-08-09 | 2018-10-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| SI3212684T1 (sl) | 2014-10-31 | 2020-04-30 | Illumina Cambridge Limited | Polimeri in DNK kopolimer premazi |
| JP2018507025A (ja) | 2015-01-29 | 2018-03-15 | サーモディクス，インコーポレイテッド | 疎水性生理活性物質粒子の送達 |
| AU2016264102A1 (en) | 2015-05-18 | 2017-12-21 | Karius, Inc. | Compositions and methods for enriching populations of nucleic acids |
| JP6914860B2 (ja) | 2015-07-01 | 2021-08-04 | カリフォルニア インスティチュート オブ テクノロジー | カチオン性粘液酸ポリマー系デリバリーシステム |
| CA2937896A1 (en) * | 2016-08-02 | 2018-02-02 | Universite De Montreal | Use of mubritinib for the treatment of poor prognosis acute myeloid leukemia |
| CN110652515A (zh) * | 2018-06-29 | 2020-01-07 | 中国科学院深圳先进技术研究院 | AMPK抑制剂Compound C在治疗肿瘤药物中的应用 |
| WO2023032891A1 (ja) | 2021-08-30 | 2023-03-09 | 東レ株式会社 | 免疫原性増強用組成物 |
| JPWO2023032892A1 (enExample) | 2021-08-30 | 2023-03-09 | ||
| CN118159285A (zh) | 2021-09-16 | 2024-06-07 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
-
2024
- 2024-03-29 JP JP2024521768A patent/JPWO2024204685A1/ja active Pending
- 2024-03-29 CN CN202480019386.2A patent/CN120957748A/zh active Pending
- 2024-03-29 WO PCT/JP2024/012990 patent/WO2024204685A1/ja not_active Ceased
- 2024-03-29 EP EP24780780.3A patent/EP4691490A1/en active Pending
- 2024-03-29 AU AU2024246833A patent/AU2024246833A1/en active Pending
- 2024-03-29 KR KR1020257028020A patent/KR20250163299A/ko active Pending
-
2025
- 2025-09-05 MX MX2025010488A patent/MX2025010488A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250163299A (ko) | 2025-11-20 |
| AU2024246833A1 (en) | 2025-09-25 |
| WO2024204685A1 (ja) | 2024-10-03 |
| MX2025010488A (es) | 2025-10-01 |
| EP4691490A1 (en) | 2026-02-11 |
| CN120957748A (zh) | 2025-11-14 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20250609 |